Guideline LDL-C Threshold Achievement in Acute Myocardial Infarction Patients: A Real-World Evidence Study Demonstrating the Impact of Treatment Intensification with PCSK9i

Figures

• 

  Fig. 1. Time to LLT dispense date from AMI date and the number of ASCVD events. AMI acute myocardial infarction, ASCVD atherosclerotic cardiovascular disease, Eze ezetimibe, LLT lipid-lowering therapy, PCSK9i proprotein convertase subtilisin/kexin type 9 inhibitor, Q quartile. a The number of ASCVD events excludes the AMI index event, but could include pre-AMI events for those who received their highest-LLT within 1 year of AMI. ASCVD events of the same condition occurring within 30 days of each other were captured as the same event; but events of different conditions were considered separate events, regardless of the time between events. b Includes statin, ezetimibe, and ezetimibe plus statins

• 

  Fig. 2. Median (95% CI) LDL-Ca in the year before and after LLT across treatment categories. CI confidence interval, Eze ezetimibe, LDL-C low-density lipoprotein cholesterol, LLT lipid-lowering therapy, PCSK9i proprotein convertase subtilisin/kexin type 9 inhibitor. a The LDL-C values are an overall average of the combined highest test result available for each 3-month window pre- and post-LLT dispense date per patient. b Any LLT combination includes statin, ezetimibe, and ezetimibe plus statins

• 

  Fig. 3. Proportion (%) of patients with LDL-C below three thresholds ((a) 1.8 mmol//l (b) 1.4 mmol/l and (c) 1.0 mmol/l) before and after LLT treatment. LDL-C low-density lipoprotein cholesterol, LLT lipid-lowering therapy, PCSK9i proprotein convertase subtilisin/kexin type 9 inhibitor. Note: the values above the bar charts indicate the difference in the proportion of patients below the threshold before versus after the LLT dispense date (difference = after—before)

• 

  Fig. 4. Median (95% CI) percent change in LDL-C in the 6 months before and after LLT by treatment category among patients with a before and after LDL-C test available. CI confidence interval, Eze ezetimibe, LDL-C low-density lipoprotein cholesterol, LLT lipid-lowering therapy, PCSK9i proprotein convertase subtilisin/kexin type 9 inhibitor. a The LDL-C values used are an overall average of the combined highest values of tests available obtained for each 3-month window pre- and post-LLT dispense date per patient. b Includes statin, ezetimibe, and ezetimibe plus statins